<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00523432</url>
  </required_header>
  <id_info>
    <org_study_id>15424A</org_study_id>
    <nct_id>NCT00523432</nct_id>
  </id_info>
  <brief_title>A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies</brief_title>
  <official_title>A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to determine the recommended phase II dose of weekly intravenous&#xD;
      topotecan in combination with a fixed dose (25 mg or 15 mg) of weekly intravenous&#xD;
      temsirolimus in patients with and without prior pelvic radiation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability of regimen</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Genital Neoplasms, Female</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A will consist of subjects without prior pelvic radiation or with radiation to a field smaller than the whole pelvis. Subjects will receive weekly CCI-779 and topotecan at the assigned dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A will consist of subjects with prior whole pelvic radiation. Subjects will receive weekly CCI-779 and topotecan at the assigned dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>Weekly doses via IV infusion. Dose will be assigned based on time of study entry.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CCI-779 (temsirolimus)</intervention_name>
    <description>Weekly 25mg dose via IV infusion.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed recurrent or metastatic ovarian carcinoma, fallopian tube&#xD;
             carcinoma, primary peritoneal carcinoma, cervical carcinoma, endometrial carcinoma,&#xD;
             vulvar carcinoma, vaginal carcinoma, or carcinosarcoma of the ovary, endometrium or&#xD;
             cervix.&#xD;
&#xD;
          -  Prior Therapy: at least one and may have up to three prior cytotoxic chemotherapeutic&#xD;
             regimens for the management of primary disease.&#xD;
&#xD;
          -  Must be at least 18 years of age.&#xD;
&#xD;
          -  GOG performance status must be 0 or 1.&#xD;
&#xD;
          -  Patients must have adequate organ and marrow function as defined below:&#xD;
&#xD;
               -  hemoglobin ≥10g/dL&#xD;
&#xD;
               -  absolute neutrophil count ≥1,500/uL&#xD;
&#xD;
               -  platelets ≥100,000/uL&#xD;
&#xD;
               -  total bilirubin below the institutional upper limit of normal&#xD;
&#xD;
               -  AST(SGOT)/ALT(SGPT) below the institutional upper limit of normal&#xD;
&#xD;
               -  creatinine below the institutional upper limit of normal&#xD;
&#xD;
               -  cholesterol ≤ 350 mg/dL (fasting)&#xD;
&#xD;
               -  triglycerides ≤ 400 mg/dL (fasting)&#xD;
&#xD;
               -  albumin ≥ 3.0 mg/dL&#xD;
&#xD;
          -  negative pregnancy test for women able to have children&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy with topotecan&#xD;
&#xD;
          -  More than 3 prior cytotoxic chemotherapeutic regimens or treatment with temsirolimus&#xD;
             or any other mTOR inhibitor&#xD;
&#xD;
          -  Concomitant hormonal therapy or radiation therapy&#xD;
&#xD;
          -  Clinically significant infections or other medical problems of significant severity&#xD;
&#xD;
          -  History of unstable angina or myocardial infarction within the past six months&#xD;
&#xD;
          -  Known brain metastases unless the metastases have been controlled by prior surgery or&#xD;
             radiotherapy, and the patient has been neurologically stable and off of steroids for&#xD;
             at least 4 weeks.&#xD;
&#xD;
          -  Any requirement for oxygen&#xD;
&#xD;
          -  Cannot be receiving potent enzyme-inducing antiepileptic drugs (EIAEDs; e.g.,&#xD;
             phenytoin, carbamazepine, phenobarbital) nor any other potent CYP3A4 inducer such as&#xD;
             rifampin or St. John's wort, as these may decrease temsirolimus levels. Use of agents&#xD;
             that potently inhibit CYP3A4 (and hence may raise temsirolimus levels), such as&#xD;
             ketoconazole, is discouraged, but not specifically prohibited.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gini Fleming, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol. 2010 Jun;117(3):473-6. doi: 10.1016/j.ygyno.2010.02.022. Epub 2010 Mar 28.</citation>
    <PMID>20347480</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>August 29, 2007</study_first_submitted>
  <study_first_submitted_qc>August 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2007</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>uterine cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>endometrial cancer</keyword>
  <keyword>vaginal cancer</keyword>
  <keyword>peritoneal cancer</keyword>
  <keyword>reproductive cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genital Neoplasms, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

